DOCSLIB.ORG

Neoplasia I Definitions, Terminology, and Morphology Nomenclature Characteristics of Benign & Malignant Neoplasms Characteri

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neoplasia I Definitions, Terminology, and Morphology Nomenclature Characteristics of Benign & Malignant Neoplasms Characteri Tissue Type Cell Type Benign Malignant Conn.Tissue Fibroblast Fibroma Fibrosarcoma Adipocyte Lipoma Liposarcoma Cartilage Chondroma Chondrosarcoma Neoplasia I Bone Osteoma Osteosarcoma Definitions, Terminology, and Vessels, etc Endothelial cells Hemangioma Angiosarcoma Meninges Meningioma Invasive Morphology meningioma Muscle Smooth muscle Leiomyoma Leiomyosarcoma Skeletal muscle Rhabdomyoma Rhabdomyosarcoma Epithelium Stratified Squamous Squamous cell Patrice Spitalnik, MD Squamous papilloma carcinoma [email protected] Ducts or glands Adenoma Adenocarcinoma Melanocytes Melanocytes Nevus Melanoma Characteristics of Benign & Malignant Neoplasms • Tissue Architecture – histologic features Cancer - second leading cause of • Cytologic features deaths in the US after CV disease • Terminology – Differentiation/anaplasia – Dysplasia – Rate of growth – Local Invasion – Metastasis Characteristics of Benign & Nomenclature Malignant Neoplasms • Neoplasia “new growth” • Tissue architecture • Neoplasms arise from genetic changes that – Benign - well circumscribed, usually allow excessive, unregulated cell encapsulated proliferation – Malignant – poorly circumscribed, lack of cell polarity and epithelial cell connections • Cell type of parenchyma + OMA 1 Characteristics, con’t. Anaplasia • Cytologic features • Neoplasm without apparent differentiation, – Benign – small, uniform cells, no visible undifferentiated cells nucleoli – Malignant – large, pleomorphic cells with large hyperchromatic nuclei, N:C ratio 1:1 (nl. 1:4), large nucleoli, irregular nuclear outlines Differentiation • Refers to original parenchymal cell, tissue appearance and function – Benign - well differentiated, resembles cell of origin with few mitoses, secretion of products, hormones, mucins, etc. – Malignant - well to poorly differentiated with numerous, bizarre mitoses Abnormal mitosis 2 Dysplasia Local Invasion • Disorderly cellular maturation • Benign – most encapsulated and cannot • If, full epithelial involvement –carcinoma in invade or spread to other sites situ, pre-invasive stage • Malignant – not encapsulated and can • HPV – cervix invade • Smoking- respiratory tract • GERD – esophagus Benign Neoplasia • Remains localized • Cannot spread to other sites • Most patients survive, but some tumor locations can cause serious problems (brain stem, spinal cord, pituitary) Rate of Growth • Benign – slower growth, some dependent on hormones, leiomyoma • Malignant – more rapid growth, areas of necrosis 3 Malignant Neoplasia • Can invade and destroy adjacent tissue • Can spread to distant sites, metastasis 4 Metastasis • Dissemination to other organs: – Seeding of body cavities (ovary) – Lymphatic spread (carcinoma) – Hematogenous dissemination (sarcoma) Steps of Successful Metastasis • Detachment of tumor cells (E-cadherin loss) • Degradation of ECM (MMP’s - overexpressed and TIMP’s - reduced) • Attachment to new ECM proteins (cleavage products of collagen and laminin bind to receptors on tumor cells - stimulate migration • Migration of tumor cells (cytokines from tumor cells direct movement, autocrine, and stromal cells produce paracrine effectors, HGF/SCF, for motility that bind to tumor cells) 5 Homing of Tumor Cells Homing of Tumor Cells • Most metastases predicted by vascular and lymphatic drainage • Some homing related to expression of endothelial adhesion molecules • Chemokines and chemokine receptors are also involved in homing. (breast ca cells-chemokine receptors: CXCR-4 and -7 bind to the chemokines CXCL12 and CCL21 on distant organs) • After extravasation, tumor cells survive only in receptive ECM and stroma 6 7 Cinical Aspects of Neoplasia 1. Epidemiology: Cancer incidence—Cancer deaths 2. Pathogenetic factors: a balance of risks 3. Clinical effects of cancer 4. Death in cancer 5. Grading and Staging 6. Diagnosis -exposures to a host of Geography: chem. & viral agents Breast Ca: US/Eur. 4-5x higher Japan -e.g. ASBESTOS: Gastric Ca: Japan 7x higher than U.S. mesothelioma Hepato. Ca: Most lethal Ca in Africa -e.g. BENZENE: (vs. 4% of deaths in US) leukemia, Hodgkin EmigrationÆassume Ca rates of region lymphoma Age Environment Heredity ? Cancer -cancer w/ age 1. Inherited Cancer Syndromes -cancer mortality -Autosomal dominant genes peak 55-75 2. Familial cancers (clusters) -under age 15, 3. Inherited syndromes of cancer causes Defective DNA Repair approx. 10% of -Autosomal rec. genes all deaths 8 Clinical Effects of Cancer 1. Cachexia -cytokinesÆ anorexia TNF: from macrophages/tumor cells -suppresses appetite -inhibits lipoprotein lipase (inhibits FFA release from lipoprot’s) Small cell Ca Proteolysis-inducing factor: -ACTH or -breaks down skeletal muscle ACTH-like subst.Æ 2. Paraneoplastic syndromes Cushing syndrome ---ADH-Æ SIADH -hormone production by tumor cells -present in 10% - 15% of pts. with cancer Squamous cell Ca 3. Venous thrombosis ÆPTH-related prot. Æhypercalcemia -mucins from Ca’s activate clotting e.g. Pancreas: Trousseau phenomenon Death in Cancer 1. Overwhelm organ function -liver: coagulation, other protein synthesis -lung: diffusion/oxygenation -pancreas: biliary obstruction/liver mets Æ anorexia 2. Pulmonary embolus (pro-thrombotic Ca’s) 3. Progressive somnolence: hypercalcemia, etc. 4. Systemic electrolyte imbalances: Æ cardiac arrhythmia Æ mentation 5. Tumor-related products: -depression/other CNS effects G /S Checkpoint: Aut. Breast Ca 1 Diagnosis of Cancer Dom. Ovarian Ca BRCA-1 -delays cell cycle to allow BRCA-2 for DNA repair by homologous recombination •History—physical—occupation—exposure Aut. Recessive •Radiology Bloom •Blood tests: tumor markers UV Syndrome •Morphologic Diagnosis light -helicase mutation -osteosarcoma -light microscopy: biopsy pyrim. Fanconi anemia -cytology (Fine Needle Aspiration—FNA) -marrow hypofunc. pyrim. -hypoplasias: -immunohistochemistry kidney/spleen/bone NER Ataxia-telangiectasia -fluorescence in situ hybridization (FISH) (nucleotide excision -mutation of ATM gene: -molecular probes, incl. gene microarray repair) pathway DNA dbl.strd. break repair Xeroderma (kinase/phosph. p53Æ -flow cytometry (lymphomas, leukemias) Pigmentosum G1 arrest or apoptosis)Æ repair -skin cancers -loss of Purkinje cells/ataxia/ immunodef./lymphoid malign. 9 Tumor Markers *Molecules in plasma produced by tumor cells Oncofetal antigens carcinoembryonic antigen gut (CEA) colon Ca; pancreas, lung,breast Ca yolk sac,liver alphafetoprotein (AFP) hepatocellular Ca, germ cell testis Ca Specific proteins PSA (prostatic specific antigen) Mucins & other glycoproteins: CA’s: carbohydrate antigens CA-125 CA-19-9 CA-15-3 ovary Bile ducts, panc. breast Hormones medullary Ca trophoblastic tumor testis HCG thyroid calcitonin (placenta) Immunohistochemistry: --monoclonal Ab to specific cell Ag’s CK7+ CK20- CK7- CK20- CK7- Cytokeratins in epith. cells: CK20+ CK7 and CK20 aneuploid adenocarcinoma normal cell with 3-8 gene small cells copies EGFR Fluorescence In Situ Hybridization (FISH) 10 Grading Staging Staging: TNM AJC (American Joint Committee) Ca AJC 11.
Load more

Recommended publications
  • Pathologic and Molecular Aspects of Anaplasia in Circumscribed Gliomas and Glioneuronal Tumors
    Brain Tumor Pathology (2019) 36:40–51 https://doi.org/10.1007/s10014-019-00336-z REVIEW ARTICLE Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors Elisabet Pujadas1 · Liam Chen1,2 · Fausto J. Rodriguez1,3 Received: 6 February 2019 / Accepted: 28 February 2019 / Published online: 11 March 2019 © The Japan Society of Brain Tumor Pathology 2019 Abstract Many breakthroughs have been made in the past decade regarding our knowledge of the biological basis of the diffuse glio- mas, the most common primary central nervous system (CNS) tumors. These tumors as a group are aggressive, associated with high mortality, and have a predilection for adults. However, a subset of CNS glial and glioneuronal tumors are char- acterized by a more circumscribed pattern of growth and occur more commonly in children and young adults. They tend to be indolent, but our understanding of anaplastic changes in these tumors continues to improve as diagnostic classifications evolve in the era of molecular pathology and more integrated and easily accessible clinical databases. The presence of ana- plasia in pleomorphic xanthoastrocytomas and gangliogliomas is assigned a WHO grade III under the current classification, while the significance of anaplasia in pilocytic astrocytomas remains controversial. Recent data highlight the association of the latter with aggressive clinical behavior, as well as the presence of molecular genetic features of both pilocytic and dif- fuse gliomas, with the recognition that the precise terminology remains to be defined. We review the current concepts and advances regarding histopathology and molecular understanding of pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas, with a focus on their anaplastic counterparts.
    [Show full text]
  • DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation
    Modern Pathology (2010) 23, S8–S13 S8 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation Sarah E Pinder Breast Research Pathology, Research Oncology, Division of Cancer Studies, King’s College London, Guy’s Hospital, London, UK Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date. Modern Pathology (2010) 23, S8–S13; doi:10.1038/modpathol.2010.40 Keywords: ductal carcinoma in situ (DCIS); breast cancer; histopathology; prognostic factors Ductal carcinoma in situ (DCIS) is a malignant, lesions, a good cosmetic result can be obtained by clonal proliferation of cells growing within the wide local excision. Recurrence of DCIS generally basement membrane-bound structures of the breast occurs at the site of previous excision and it is and with no evidence of invasion into surrounding therefore better regarded as residual disease, as stroma.
    [Show full text]
  • Ductal Carcinoma in Situ Management Update
    Breast series • CLINICAL PRACTICE Ductal carcinoma in situ Management update Kirsty Stuart, BSc (Med), MBBS, FRANZCR, is a radiation oncologist, NSW Breast Cancer Institute, Westmead Hospital, New South Wales. John Boyages, MBBS, FRANZCR, PhD, is Associate Professor, University of Sydney, and Executive Director and radiation oncologist, NSW Breast Cancer Institute, Westmead Hospital, New South Wales. Meagan Brennan, BMed, FRACGP, DFM, FASBP, is a breast physician, NSW Breast Cancer Institute, Westmead Hospital, New South Wales. [email protected] Owen Ung, MBBS, FRACS, is Clinical Associate Professor, University of Sydney, and Clinical Services Director and breast and endocrine surgeon, NSW Breast Cancer Institute, Westmead Hospital, New South Wales. This ninth article in our series on breast disease will focus on ductal carcinoma in situ of the breast – a proliferation of potentially malignant cells within the lumen of the ductal system. An overview of the management of ductal carcinoma in situ including pathology, clinical presentation and relevant investigations is presented, and the roles and dilemmas of surgery, radiotherapy and endocrine therapy are discussed. The incidence of ductal carcinoma in situ that may present as a single grade or a inflammation. Myoepithelial stains are used (DCIS) of the breast has risen over the past combination of high, intermediate or low to help identify a breach in the duct lining. 15 years. This is in part due to the introduction grades. There are various histological patterns However, if there is any doubt, a second of screening mammography. The diagnosis of DCIS and more than one of these may be pathological opinion may be worthwhile.
    [Show full text]
  • SOMATIC MUTATIONS AS a FACTOR in the PRODUC- TION of CANCER for Nearly Thirty Years the Phenomenon Known by Von Hanse- Mann's
    SOMATIC MUTATIONS AS A FACTOR IN THE PRODUC- TION OF CANCER A CRITICAL REVIEW OF v. HANSEMANN’S THEORY OF ANAPLASIA IN THE LIGHT OF MODERN KNOWLEDGE OF GENETICS R. C. WHITMAN From the Henry S. Denison Research Laboratories of the University of Colorado, Received for publication, March 4, 1918 For nearly thirty years the phenomenon known by von Hanse- mann’s term, anaplasia, has been widely used among patholog- ists to describe and exphin the origin of cancer cells. Any well established facts, therefore, which throw added light upon the nature of the process of anaplasia itself and any possible relation it may have to cancer genesis must be important and significant. The term anaplasia has been, however, so loosely used that it will be worth while to review at length von Hansemann’s theory in order that we may start with a clear conception of what the word really means. The pleomorphism of cancer cells and the irregular, atypical mitoses so characteristic of their nuclei had been observed and carefully studied since the middle of the nine- teenth century. Arnold (Virch. Arch., vol. 79, cited by von Hansemann (l)),observing irregularities in the mitotic process itself, had inferred that thesemight be of fundamental significance. A voluminous literature dealing with the mitoses in cancer cells and other forms of rapidly proliferating tissues had already ac- cumulated when von Hansemann (1) undertook a further inves- tigation in the same field. In a carcinoma of the larynx he found besides a great abundance of normal mitotic figures, large numbers of tripolar and multipolar divisions and other departures from the normal type already observed and described by earlier writers; and in addition many hyperchromatic and hypochromatic mitoses, the hypochromatism consisting not merely in a reduction of the amount of chromatin in the chromosoines but rather in an 181 182 R.
    [Show full text]
  • Nodal Metastases from Laryngeal Carcinoma and Their Correlation with Certain Characteristics of the Primary Tumor
    NODAL METASTASES FROM LARYNGEAL CARCINOMA AND THEIR CORRELATION WITH CERTAIN CHARACTERISTICS OF THE PRIMARY TUMOR Kamaljit Kaur ~, Nishi Sonkhya 2, A.S. Bapna 3 Key Words : Carcinoma larynx, nodal metastases. INTRODUCTION nodal metastases progresses in an orderly manner with Cancer of the larynx represents about 2% of the total the first site of metastasis being the sentinel node. cancer risk and is the most common head and neck cancer (skin excluded). It has been consistently observed by Lymphatic metastasis is the most important mechanism various authors that the status of cervical lymph nodes is in the spread of head and neck squamous cell carcinoma. the single most important prognostic factor in laryngeal Multiple clinical studies have demonstrated that the carcinoma and the probability of 5 year survival, regardless distribution of cervical lymph node metastases is indeed of the treatment rendered, reduces by 50% once the tumor predictable in patients with previously untreated squamous dissemination to the regional lymph nodes has taken place. cell carcinoma of the upper aerodigestive tract. The rate For this reason, studies dealing with the probability of of metastasis probably reflects the aggressiveness of the nodal metastases are important in making therapeutic primary tumor and is an important prognosticator. Not decisions. only the presence, but also the number of nodal metastases, their level in the neck, the size of the nodes and the presence Although the credit for first injection studies of laryngeal of extra-capsular spread are important prognostic feature. lymphatics goes to Hajek in 1891, it was the monumental study of laryngeal lymphatics by injections of dyes and There is a need to identify pretreatment factors that can radioisotopes by Pressman et al in 1956 that provided differentiate high risk from low risk patients with respect excellent documentation of the anatomical to occult metastases.
    [Show full text]
  • Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring
    cancers Review Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring Felix Behling 1,2,* , Johann-Martin Hempel 2,3 and Jens Schittenhelm 2,4 1 Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 2 Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany; [email protected] (J.-M.H.); [email protected] (J.S.) 3 Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 4 Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany * Correspondence: [email protected] Simple Summary: Meningiomas are benign tumors of the meninges and represent the most common primary brain tumor. Most tumors can be cured by surgical excision or stabilized by radiation therapy. However, recurrent cases are difficult to treat and alternatives to surgery and radiation are lacking. Therefore, a reliable prognostic marker is important for early identification of patients at risk. The presence of infiltrative growth of meningioma cells into central nervous system tissue has been identified as a negative prognostic factor and was therefore included in the latest WHO classification for CNS tumors. Since then, the clinical impact of CNS invasion has been questioned by different retrospective studies and its removal from the WHO classification has been suggested. Citation: Behling, F.; Hempel, J.-M.; There may be several reasons for the emergence of conflicting results on this matter, which are Schittenhelm, J. Brain Invasion in discussed in this review together with the potential and future perspectives of the role of CNS Meningioma—A Prognostic Potential invasion in meningiomas.
    [Show full text]
  • Paraneoplastic Neurologic Syndromes
    DO I:10.4274/tnd.05900 Turk J Neurol 2018;24:63-69 Case Report / Olgu Sunumu Paraneoplastic Neurologic Syndromes: Rare But More Common Than Expected Nine Cases with a Literature Review Paraneoplastik Nörolojik Sendromlar: Nadir Ancak Beklenenden Daha Sık Dokuz Olgu ile Literatür Derlemesi Hülya Uluğut Erkoyun, Sevgin Gündoğan, Yaprak Seçil, Yeşim Beckmann, Tülay Kurt İncesu, Hatice Sabiha Türe, Galip Akhan Izmir Katip Celebi University, Atatürk Training and Research Hospital, Department of Neurology, Izmir, Turkey Abstract Paraneoplastic neurologic syndromes (PNS) are rare disorders, which are remote effects of cancer that are not caused by the tumor, its metastasis or side effects of treatment. We had nine patients with PNS; two of our patients had limbic encephalitis, but one had autoimmune limbic encephalitis with no malignancy; two patients had subacute cerebellar degeneration; three had Stiff-person syndrome; one had Lambert-Eaton myasthenic syndrome; and the remaining patient had sensory neuronopathy. In most patients, the neurologic disorder develops before the cancer becomes clinically overt and the patient is referred to a neurologist. Five of our patients’ malignancies had been diagnosed in our clinic after their neurologic symptoms became overt. PNS are more common than expected and neurologists should be aware of the variety of the clinical presentations of these syndromes. When physicians suspect PNS, cancer screening should be conducted. The screening must continue even if the results are negative. Keywords: Paraneoplastic, neurologic syndromes, neurogenic autoantibodies Öz Paraneoplastik nörolojik sendromlar (PNS), kanserin doğrudan, metastaz ya da tedavi yan etkisine bağlı olmayan, uzak etkisi ile ortaya çıkan nadir hastalıklardır. Dokuz PNS’li hastanın ikisi limbik ensefalitti fakat bunlardan biri otoimmün limbik ensefalitti ve malignitesi yoktu.
    [Show full text]
  • VARYING DEGREES of MALIGNANCY in CANCER of the BREAST Differences in the Degree of Malignancy of Malignant Tumors Have Been Reco
    VARYING DEGREES OF MALIGNANCY IN CANCER OF THE BREAST ROBERT 13. GREENOUGH BOSTON Differences in the degree of malignancy of malignant tumors have been recognized by pathologists for many years. Indeed, Virchow’s original conception of a malignant tumor was one composed of cells, derived from the tissue cells of the individual, but differing from the normal cells in the rapidity and independ- ence of their growth. Hansemann (1) carried this idea somewhat further and intro- duced the word “anaplasia” to indicate the process by which cancer cells came to differ from the normal type cell of the body tissue concerned. Anaplasia involves a loss of differentiation and an increase of reproductive power, so that the anaplastic cell fulfils only in abortive fashion, if at all, its normal function, such as secretion or keratinization; while it shows by increased number of mitotic figures, and especially by the irregularity and abnormality of its nuclear chromatic elements and figures, the increase in rapidity of cell division and of cell growth which is characteristic of malignancy. X number of attempts have been made to grade the malig- nancy of different breast tumors by distinguishing their histo- logical characteristics, such as adenocarcinoma, medullary, scirrhus, colloid, etc. ; but with the exception of adenocarcinoma and colloid, these divisions have proved of little value in prognosis. There the matter rested till 1921, when, under the influence of MacCarty (2) of the Mayo Clinic, Broders published a paper suggesting the classification of cancer tissue according to the degree of malignancy, as estimated by loss of differentiation and increase of reproductive characteristics.
    [Show full text]
  • Histological Typing of Prostate Tumours
    HISTOLOGICAL TYPING OF PROST ATE TUMOURS INTERNATIONAL HISTOLOGICAL CLASSIFICATION OF TUMOURS No. 22 HISTOLOGICAL TYPING OF PROSTATE TUMOURS F. K. MOSTOFI Head, WHO Collaborating Centre for the Histological Classification of Male Urogenital Tract Tumours, Armed Forces Institute of Pathology, Washington, DC, USA '- in collaboration with I. SESTERHENN L. H. SOBIN Armed Forces Institute of Pathologist, Pathology, World Health Organization, Washington, DC, USA Geneva, Switzer/and and pathologists in eight countries WORLD HEALTH ORGANIZATION GENEVA 1980 ISBN 92 4 176022 2 ©World Health Organization 1980 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or in toto, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organi­ zation welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. Authors alone are responsible for views expressed in this publication.
    [Show full text]
  • Role of IQGAP1 in Carcinogenesis
    cancers Review Role of IQGAP1 in Carcinogenesis Tao Wei and Paul F. Lambert * McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA; [email protected] * Correspondence: [email protected] Simple Summary: IQ motif-containing GTPase-activating protein 1 (IQGAP1) is a signal scaffolding protein that regulates a range of cellular activities by facilitating signal transduction in cells. IQGAP1 is involved in many cancer-related activities, such as proliferation, apoptosis, migration, invasion and metastases. In this article, we review the different pathways regulated by IQGAP1 during cancer development, and the role of IQGAP1 in different types of cancer, including cancers of the head and neck, breast, pancreas, liver, colorectal, stomach, and ovary. We also discuss IQGAP10s regulation of the immune system, which is of importance to cancer progression. This review highlights the significant roles of IQGAP1 in cancer and provides a rationale for pursuing IQGAP1 as a drug target for developing novel cancer therapies. Abstract: Scaffolding proteins can play important roles in cell signaling transduction. IQ motif- containing GTPase-activating protein 1 (IQGAP1) influences many cellular activities by scaffolding multiple key signaling pathways, including ones involved in carcinogenesis. Two decades of studies provide evidence that IQGAP1 plays an essential role in promoting cancer development. IQGAP1 is overexpressed in many types of cancer, and its overexpression in cancer is associated with lower survival of the cancer patient. Here, we provide a comprehensive review of the literature regarding the oncogenic roles of IQGAP1. We start by describing the major cancer-related signaling pathways Citation: Wei, T.; Lambert, P.F.
    [Show full text]
  • Paraneoplastic Syndromes in Lung Cancer and Their Management
    359 Review Article Page 1 of 9 Paraneoplastic syndromes in lung cancer and their management Asad Anwar1, Firas Jafri1, Sara Ashraf2, Mohammad Ali S. Jafri3, Michael Fanucchi3 1Department of Internal Medicine, Westchester Medical Center, Valhalla, NY, USA; 2Department of Hematology/Oncology, Marshall University, Huntington, WV, USA; 3Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Mohammad Ali S. Jafri, MD. Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA. Email: [email protected]. Abstract: Paraneoplastic syndromes are most frequently associated with lung cancer. This review considers a variety paraneoplastic syndromes associated with lung cancer and discusses their pathophysiology, clinical features and management options. Keywords: Paraneoplastic syndromes; lung cancer; thoracic oncology Submitted Feb 12, 2019. Accepted for publication Apr 25, 2019. doi: 10.21037/atm.2019.04.86 View this article at: http://dx.doi.org/10.21037/atm.2019.04.86 Introduction PTHrP production (parathyroid hormone related-protein), it is referred to as HHM. Paraneoplastic syndromes refer to the remote effects HHM is observed in a variety of malignancies such as associated with malignancy which are unrelated to direct breast, renal, multiple myeloma and lung; squamous cell tumor invasion or metastases (1). These may occur before is the most frequently observed subtype (3-5). Osteolytic the cancer is diagnosed and can be independent in their metastases are another significant cause of hypercalcemia in severity to the stage of the primary tumor.
    [Show full text]
  • Predictors of Invasion and Axillary Lymph Node Metastasis in Patients with a Core Biopsy Diagnosis of Ductal Carcinoma in Situ: an Analysis of 255 Cases
    ORIGINAL ARTICLE Predictors of Invasion and Axillary Lymph Node Metastasis in Patients with a Core Biopsy Diagnosis of Ductal Carcinoma In Situ: An Analysis of 255 Cases Jeong S. Han, MD, PhD, Kyle H. Molberg, MD and Venetia Sarode, MD Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas n Abstract: The diagnosis of ductal carcinoma in situ (DCIS) using core biopsy does not ensure the absence of invasion on final excision. We performed a retrospective analysis of 255 patients with DCIS who had subsequent excision. Clinical, radiologic, and pathologic findings were correlated with risk of invasion and sentinel lymph node (SLN) metastasis. Of 255 patients with DCIS, 199 had definitive surgery and 52 (26%) had invasive ductal carcinoma (IDC) on final excision. Extent of abnormal microcalcification on mammography, and presence of a radiologic ⁄ palpable mass and solid type of DCIS were significantly associated with invasion on final excision. Sentinel lymph node biopsy was performed in 131 (65.8%) patients of whom 18 (13.4%) had metastasis. Size of IDC and extent of DCIS on final pathology were significantly associated with positive SLN. Micrometastasis and isolated tumor cells comprised majority (71.4%) of the metastases in DCIS. SLN biopsy should be considered in those with high risk DCIS. n Key Words: Ductal carcinoma in situ, invasion, metastasis, sentinel lymph node biopsy uctal carcinoma in situ (DCIS) is a clonal prolif- require additional surgery, and accurate SLN mapping Deration of malignant cells confined to the ductal- could be compromised. On the other hand, for the lobular units without invading the periductal stroma.
    [Show full text]